Predicting late recurrence in ER-positive breast cancer
Crossref DOI link: https://doi.org/10.1038/s41571-019-0228-y
Published Online: 2019-05-15
Published Print: 2019-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cuzick, Jack
Text and Data Mining valid from 2019-05-15
Version of Record valid from 2019-05-15
Article History
First Online: 15 May 2019
Competing interests
: The author declares that he is a consultant for Myriad Genetics, who market the EndoPredict assay (EPclin).